Che-Kai Tsao MD MS
Genitourinary Oncology
System Chief of Solid Tumor Oncology at Northwell Health Cancer Institute
RJ Zuckerberg Cancer Center450 Lakeville RdNew Hyde Park, NY 11042
Overview of Dr. Tsao
Dr. Che-Kai Tsao is an oncology specialist based in New Hyde Park, NY, with subspecialization in genitourinary oncology. He completed his fellowship in hematology and medical oncology at the Icahn School of Medicine at Mount Sinai after earning his medical degree from SUNY Downstate Medical Center College of Medicine. His professional roles include serving as System Chief of Solid Tumor Oncology at Northwell Health and previous tenures at The Mount Sinai Hospital and Mount Sinai Hospital of Queens. Dr. Tsao's experience encompasses genitourinary cancer, renal cell carcinoma, and clinical research, highlighted by publications in reputable journals and active participation in clinical trials. His contributions to the field have earned him several awards, including the Solid Tumor Faculty Teacher of the Year from Tisch Cancer Institute in 2023.
Education & Training
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 2009 - 2012
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 2005 - 2008
State University of New York Downstate Medical Center College of MedicineClass of 2005
New York UniversityB.A., Mathematics and Economics, Cum Laude, 1996 - 2000
Certifications & Licensure
NY State Medical License 2008 - 2027
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Solid Tumor Faculty Teacher of the Year Tisch Cancer Institute, 2023
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2017
- Fellow Physician of the Year Mount Sinai Hospital, 2012
Clinical Trials
- A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney Start of enrollment: 2017 Jul 07
- A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) Start of enrollment: 2018 Dec 18
- A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors Start of enrollment: 2019 Aug 12
Publications & Presentations
PubMed
- External control arms can validate treatment efficacy in single-arm studies.Eric J Miller, Saad Atiq, Jonathan F Anker, Che-Kai Tsao
Journal of the National Cancer Institute. 2026-05-18 - CLO26-075: Are PARP Inhibitors Effective Beyond Homologous Recombination Repair-Deficiency in Castration-Resistant Prostate Cancer? A Meta-Analysis.Susu Zhou, Devashish Desai, Sam Benjamin, Che-Kai Tsao
Journal of the National Comprehensive Cancer Network. 2026-03-31 - CLO26-075: Are PARP Inhibitors Effective Beyond Homologous Recombination Repair-Deficiency in Castration-Resistant Prostate Cancer? A Meta-Analysis.Susu Zhou, Devashish Desai, Sam Benjamin, Che-Kai Tsao
Journal of the National Comprehensive Cancer Network. 2026-03-31
Journal Articles
- Activity of Platinum-Based Chemotherapy in Patients with Advanced Prostate Cancer with and Without DNA Repair Gene AberrationsHimisha Beltran, Che-Kai Tsao, Tomasz M Beer, JAMA Network Open
- Endocrine therapy for prostate cancer: review of the latest clinical evidenceTsao CK, Seng SM, Galsky MD, Oh WK, Clinical Investigation, 4/1/2011
- Review of cabazitaxel for the treatment of hormone-refractory prostate cancerTsao CK, Seng SM, Oh WK, Galsky MD, Clinical Medicine Insights: Oncology, 1/1/2011
Press Mentions
Study on Veterans Reveals Real-World Survival Outcomes for Targeted Therapies in Advanced Renal Cell CarcinomaNovember 18th, 2019
Nivolumab Trial Failure Raises the Question of Brain Imaging in Kidney CancerJuly 8th, 2019- JAVELIN Renal 101: Combination Therapy vs Standard of Care in Advanced RCCMarch 6th, 2019
Professional Memberships
- Member
- Member
Other Languages
- Chinese (Mandarin), Taiwanese
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPOGHI PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
